Takeda's vedolizumab gets EU nod for both IBD indications
This article was originally published in Scrip
Executive Summary
The EMA's Committee for Medicinal Products for Human Use ( CHMP) has recommended granting a approval for Takeda Pharmaceuticals' Entyvio (vedolizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis or Crohn's disease, who have had an inadequate response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist therapy.